Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated 26 minutes ago
Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing
26 minutes ago
After a four-month investigation, Nature Medicine has decided to pull a viral...
RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic
about 2 hours ago
Amid a bustling fundraising week for biotechs, the U.K.’s RQ Bio is...
Novartis pays Antares $105M to illuminate undruggable cancer targets
about 2 hours ago
Novartis is paying Antares Therapeutics $105 million upfront in a deal worth...
Abbott pens blood-based Alzheimer's testing pact with ALZpath
about 2 hours ago
Abbott has become the latest company to team up with Alzheimer’s disease...
Access Vascular taps Medline to help roll out new line of catheters
about 3 hours ago
Access Vascular, a Massachusetts-based device maker that focuses on intravenous catheters, inked...
BIO 2026: Flagship inks research collaboration with Saudi sovereign wealth fund company
about 3 hours ago
On Tuesday afternoon at the 2026 Biotechnology Innovation Organization conference in San...
Insulet hires Convatec, Eli Lilly alum as new R&D chief
about 4 hours ago
Omnipod maker Insulet has hired Divakar Ramakrishnan, Ph.D., as its new Chief...
Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact
about 4 hours ago
Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to...
Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet
about 4 hours ago
Half a year after toppling Genentech’s eye medicine giant Vabysmo in an...
Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push
about 21 hours ago
An under-the-radar Bay Area biotech has brought in a $190 million series...
Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China
about 22 hours ago
The focus of the company is SERP-01, an in vivo base editing...
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
1 day ago
Eli Lilly and Astellas have emerged as “stalking horse bidders” for certain...